Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | What does the future hold for lifileucel in treating sarcoma?

Lauren Banks, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the potential of a lifileucel for select patients with sarcoma, highlighting the development of the Phase II SARATOGA trial (NCT07741877). The trial is designed to build on the foundation of a previous study ((NCT05607095) and determine whether the signal seen will translate into a viable treatment option for patients. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So that’s a really good question. I think it’s evolving, and my hope is it’s evolving towards potentially a new treatment option for select patients. So I think what was I think most remarkable is that this study, which was sponsored by Iovance, did serve as a foundation for the development design of a phase two trial sponsored by Iovance that’s now open, called SARATOGA , across multiple U...

So that’s a really good question. I think it’s evolving, and my hope is it’s evolving towards potentially a new treatment option for select patients. So I think what was I think most remarkable is that this study, which was sponsored by Iovance, did serve as a foundation for the development design of a phase two trial sponsored by Iovance that’s now open, called SARATOGA , across multiple U.S. centers, including MSK. And so that trial is now designed to interrogate the efficacy with that in mind. And specifically asking that question is that signal that we saw going to pan out when we think about this as this as a treatment option for our patients and so my hope is that it’s moving and evolving towards you know on that route right it’s a hard regulatory pathway especially in a rare disease and our trials are smaller and so we have a little bit of a hill to climb but my hope is we’ll get there

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.